0000950170-24-098807.txt : 20240819 0000950170-24-098807.hdr.sgml : 20240819 20240819202320 ACCESSION NUMBER: 0000950170-24-098807 CONFORMED SUBMISSION TYPE: 3 PUBLIC DOCUMENT COUNT: 2 CONFORMED PERIOD OF REPORT: 20240814 FILED AS OF DATE: 20240819 DATE AS OF CHANGE: 20240819 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Saito Chihiro CENTRAL INDEX KEY: 0002034025 ORGANIZATION NAME: FILING VALUES: FORM TYPE: 3 SEC ACT: 1934 Act SEC FILE NUMBER: 001-40656 FILM NUMBER: 241222355 MAIL ADDRESS: STREET 1: C/O TENAYA THERAPEUTICS, INC. STREET 2: 171 OYSTER POINT BLVD., SUITE 500 CITY: SOUTH SAN FRANCISCO STATE: CA ZIP: 94080 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Tenaya Therapeutics, Inc. CENTRAL INDEX KEY: 0001858848 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 813789973 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 171 OYSTER POINT BLVD., SUITE 500 CITY: SOUTH SAN FRANCISCO STATE: CA ZIP: 94080 BUSINESS PHONE: 415-865-2066 MAIL ADDRESS: STREET 1: 171 OYSTER POINT BLVD., SUITE 500 CITY: SOUTH SAN FRANCISCO STATE: CA ZIP: 94080 3 1 ownership.xml 3 X0206 3 2024-08-14 0 0001858848 Tenaya Therapeutics, Inc. TNYA 0002034025 Saito Chihiro C/O TENAYA THERAPEUTICS, INC. 171 OYSTER POINT BLVD., 5TH FLOOR SOUTH SAN FRANCISCO CA 94080 false true false false SVP, Accounting and Fin. Ops. Common Stock 7832 D Common Stock 41137 D Stock Option (Right to Buy) 20.65 2022-09-30 2031-09-29 Common Stock 49000 D Stock Option (Right to Buy) 15.19 2022-03-15 2032-02-14 Common Stock 7500 D Stock Option (Right to Buy) 3.06 2023-03-15 2033-02-14 Common Stock 28125 D Stock Option (Right to Buy) 5.22 2024-03-23 2034-02-22 Common Stock 32750 D Consists of restricted stock units ("RSUs") granted pursuant to the Tenaya Therapeutics, Inc. 2021 Equity Incentive Plan. Each RSU is the economic equivalent of one share of Tenaya Therapeutics, Inc. common stock. Certain of the RSUs have vested and are reported above and the remaining 32,772 RSUs will vest on various dates between August 15, 2024 and February 15, 2028, subject to Ms. Saito's continued service through the applicable vesting date. Option granted pursuant to the Tenaya Therapeutics, Inc. 2021 Equity Incentive Plan. 34,708 shares subject to the option are fully vested and exercisable as of the date of this filing. The option vested as to 1/4th of the original number of shares subject to the option on the one-year anniversary of the grant date, and thereafter as to 1/48th of the original number of shares subject to the option on each monthly anniversary of the grant date through the date of this filing. The unvested portion of the option will continue to vest as to 1/48th of the original number of shares subject to the option on each monthly anniversary of the grant date. Option granted pursuant to the Tenaya Therapeutics, Inc. 2021 Equity Incentive Plan. 4,687 shares subject to the option are fully vested and exercisable as of the date of this filing. The option vested as to 1/48th of the original number of shares subject to the option on the one-month anniversary of the grant date, and thereafter as to 1/48th of the original number of shares subject to the option on each monthly anniversary of the grant date through the date of this filing. The unvested portion of the option will continue to vest as to 1/48th of the original number of shares subject to the option on each monthly anniversary of the grant date. Option granted pursuant to the Tenaya Therapeutics, Inc. 2021 Equity Incentive Plan. 10,546 shares subject to the option are fully vested and exercisable as of the date of this filing. The option vested as to 1/48th of the original number of shares subject to the option on the one-month anniversary of the grant date, and thereafter as to 1/48th of the original number of shares subject to the option on each monthly anniversary of the grant date through the date of this filing. The unvested portion of the option will continue to vest as to 1/48th of the original number of shares subject to the option on each monthly anniversary of the grant date. Option granted pursuant to the Tenaya Therapeutics, Inc. 2021 Equity Incentive Plan. 3,411 shares subject to the option are fully vested and exercisable as of the date of this filing. The option vested as to 1/48th of the original number of shares subject to the option on the one-month anniversary of the grant date, and thereafter as to 1/48th of the original number of shares subject to the option on each monthly anniversary of the grant date through the date of this filing. The unvested portion of the option will continue to vest as to 1/48th of the original number of shares subject to the option on each monthly anniversary of the grant date. /s/ Jennifer Drimmer Rokovich 2024-08-19 EX-24 2 tnya-ex24.htm EX-24 EX-24

POWER OF ATTORNEY

 

The undersigned, as a Section 16 reporting person of Tenaya Therapeutics, Inc. (the "Company"), hereby constitutes and appoints Faraz Ali and Jennifer Drimmer Rokovich, and each of them, as the undersigned's true and lawful attorney-in-fact to:

 

1. complete and execute Forms 3, 4 and 5 and other forms and all amendments thereto as such attorney-in-fact shall in his discretion determine to be required or advisable pursuant to Section 16 of the Securities Exchange Act of 1934 (as amended) and the rules and regulations promulgated thereunder, or any successor laws and regulations, as a consequence of the undersigned's ownership, acquisition or disposition of securities of the Company; and

 

2. do all acts necessary in order to file such forms with the SEC, any securities exchange or national association, the Company and such other person or agency as the attorneys-in-fact shall deem appropriate.

 

The undersigned hereby ratifies and confirms all that said attorneys-in-fact and agents shall do or cause to be done by virtue hereof. The undersigned acknowledges that the foregoing attorneys-in-fact, in serving in such capacity at the request of the undersigned, are not assuming, nor is the Company assuming, any of the undersigned's responsibilities to comply with Section 16 of the Securities Exchange Act of 1934 (as amended).

 

This Power of Attorney shall remain in full force and effect until the undersigned is no longer required to file Forms 3, 4 and 5 with respect to the undersigned's holdings of and transactions in securities issued by the Company, unless earlier revoked by the undersigned in a signed writing delivered to the Company and the foregoing attorneys-in-fact.

 

IN WITNESS WHEREOF, the undersigned has caused this Power of Attorney to be executed as of August 14, 2024.

 

Signature: /s/ Chihiro Saito

 

Print Name: Chihiro Saito